First-in-human UX016 study for GNE Myopathy, Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical registered a first-in-human clinical trial on ClinicalTrials.gov for UX016, an investigational therapy for GNE Myopathy (NCT07511556). GNE Myopathy is a rare, progressive autosomal recessive muscle disease. The registration provides standard trial metadata including study design, eligibility criteria, and investigator information.

This is a routine clinical trial registration posting with no compliance obligations for external parties. Sponsors and clinical investigators involved in the study should ensure continued adherence to FDA clinical trial registration requirements and ICH/GCP guidelines. The registration does not create new regulatory obligations beyond existing clinical research requirements.